Evidence map›Paper›PMID 39225701›Full record

ArticleThe clinical respiratory journal2024

Bronchoscopic Interventional Therapy Combined With Pembrolizumab in the Treatment of Pulmonary Large Cell Neuroendocrine Carcinoma: A Case Report.

Yingyi Fan, Yingying Wang, Yanrong Ji, Shuang Li, Jian Zhang, Xingliang Hao

Abstract readCase Reports
In one paragraph

Article in The clinical respiratory journal, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors.

Yingyi FanDepartment of Respiratory and Critical Care Medicine, Shengli Oilfield Central Hospital, Dongying, China.ORCID https://orcid.org/0009-0009-4571-7340
Yingying WangClinical Pharmacy of Pharmacy Department, Shengli Oilfield Central Hospital, Dongying, China.
Yanrong JiDepartment of Respiratory and Critical Care Medicine, Shengli Oilfield Central Hospital, Dongying, China.
Shuang LiDepartment of Respiratory and Critical Care Medicine, Shengli Oilfield Central Hospital, Dongying, China.
Jian ZhangDepartment of Respiratory and Critical Care Medicine, Shengli Oilfield Central Hospital, Dongying, China.
Xingliang HaoDepartment of Respiratory and Critical Care Medicine, Shengli Oilfield Central Hospital, Dongying, China.

Funding

Medical and Health Science and Technology Development Project of Shandong Province 202013010179
6 · The paper itself

Abstract

This study reports a significant clinical outcome following the use of bronchoscopic interventional therapy combined with pembrolizumab for treating pulmonary large cell neuroendocrine carcinoma (LCNEC), showcasing a novel approach in managing this aggressive cancer.

Indexed as

Antibodies, Monoclonal, HumanizedBronchoscopyCarcinoma, NeuroendocrineLung NeoplasmsAntineoplastic Agents, ImmunologicalCarcinoma, Large CellCombined Modality TherapyHumansTomography, X-Ray ComputedTreatment OutcomeAntibodies, Monoclonal, HumanizedAntineoplastic Agents, Immunologicalpembrolizumabcentral airway stenosislarge cell neuroendocrine carcinoma of the lungpembrolizumabphotodynamic therapy

Identifiers

PMID39225701
PMCPMC11370624

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.